New drug combo aims to boost platelets in bleeding disorder
NCT ID NCT07315373
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing three different daily doses of zanubrutinib (80, 160, or 240 mg) combined with high-dose dexamethasone in 60 adults newly diagnosed with immune thrombocytopenia (ITP). The goal is to find the safest and most effective dose that helps maintain platelet counts above 30,000 without bleeding. Participants will take the drug for 26 weeks, and the study will measure how many achieve a sustained response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zanubrutinib (a targeted drug) combined with high-dose dexamethasone (a steroid)
What this could lead to
If it works, this could point toward a new treatment option for adults with immune thrombocytopenia that may help maintain safe platelet levels.
What could go wrong
This is a very early, small phase 1 trial, so it is not yet known if the drug works or is safe. Side effects from zanubrutinib or the steroid are possible, and the results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••